SCHEMBL13221035

SCHEMBL13221035

COc1cc(OC)cc(-c2cc3nccn3c(Nc3cc(C4CC4)[nH]n3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 13/20 0.51
▸ MAP4K2 Q12851 3/20 0.43
▸ SYK P43405 2/20 0.41
▸ PAK1 Q13153 1/20 0.41
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CCNA1 P78396 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ INSR P06213 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ LYN P07948 1/20 0.39
▸ RET P07949 1/20 0.39
▸ ROS1 P08922 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ FER P16591 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ BLK P51451 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13221032 0.92 IGF1R (0.52) IGF1RMAP4K2SYKPAK1CCNA2
SCHEMBL13221028 0.87 IGF1R (0.45) IGF1RSYKPAK1
SCHEMBL13221049 0.86 IGF1R (0.44) IGF1RMAP4K2SYKPAK1CDK2
SCHEMBL13221042 0.86 SYK (0.58) IGF1RMAP4K2SYKPAK1CDK2
SCHEMBL13221031 0.85 PAK1 (0.44) IGF1RSYKPAK1
SCHEMBL13221060 0.85 IGF1R (0.44) IGF1RSYKPAK1NTRK1
SCHEMBL13220997 0.85 NEK1 (0.49) IGF1RPAK1
SCHEMBL13221039 0.83 PAK1 (0.42) IGF1RSYKPAK1
SCHEMBL13221056 0.83 NEK1 (0.47) IGF1RPAK1CCNA2CDK2CCNA1
SCHEMBL13221048 0.83 IGF1R (0.45) IGF1RMAP4K2SYKPAK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216765-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 IGF1R 787/4885MAP4K2 16/4885SYK 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback